找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: New Therapies in Advanced Cutaneous Malignancies; Piotr Rutkowski,Mario Mandalà Book 2021 The Editor(s) (if applicable) and The Author(s),

[复制链接]
楼主: Mosquito
发表于 2025-3-23 11:10:46 | 显示全部楼层
发表于 2025-3-23 14:31:09 | 显示全部楼层
发表于 2025-3-23 22:05:05 | 显示全部楼层
Dabrafenib and Trametinibta confirming significant improvement in overall survival and progression-free survival over vemurafenib therapy or dabrafenib alone. The next indication in melanoma for the combination of these drugs is adjuvant therapy, which was approved on the basis of long-term outcomes of study resulting in a
发表于 2025-3-23 22:42:31 | 显示全部楼层
发表于 2025-3-24 05:57:51 | 显示全部楼层
发表于 2025-3-24 09:26:20 | 显示全部楼层
Vismodegib and differentiation. Hh pathway is inactive in most normal adult tissues, and this pathway reactivation is involved in the pathogenesis of several malignancies like basal cell carcinoma. Vismodegib has been approved for locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy
发表于 2025-3-24 12:34:50 | 显示全部楼层
发表于 2025-3-24 17:57:34 | 显示全部楼层
发表于 2025-3-24 21:10:37 | 显示全部楼层
Nivolumab in Melanoma: An Overview of Medical Literature and Future Perspectivesand adjuvant treatment of melanoma. The first checkpoint inhibitor to be approved by FDA and EMA for treatment of melanoma was ipilimumab, a human cytotoxic T-lymphocyte antigen 4 (CTLA-4) antibody, based on proven benefit in terms of overall survival and recurrence-free survival in advanced and ear
发表于 2025-3-25 00:41:36 | 显示全部楼层
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-5-18 13:50
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表